We are live on ! Find out more
KYNB

Kyntra Bio
KYNB

100 hedge funds and large institutions have $62.1M invested in Kyntra Bio in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 33 increasing their positions, 31 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,862% more call options, than puts

Call options by funds: $1.72M | Put options by funds: $58K

5% more capital invested

Capital invested by funds: $59M → $62.1M (+$3.17M)

6% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 31

0.07% more ownership

Funds ownership: 2.78% → 2.85% (+0.07%)

9% less funds holding

Funds holding: 110 → 100 (-10)

45% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 22

Holders
100
Holders Change
-10
Holders Change %
-9.09%
% of All Funds
1.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
33
Reduced
31
Closed
22
Calls
$1.72M
Puts
$58K
Net Calls
+$1.66M
Net Calls Change
-$15K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$1.13M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$694K
3
Citadel Advisors
Citadel Advisors
Florida
+$688K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$515K
5
PI
Pennant Investors
New Jersey
+$464K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.22M
2
Millennium Management
Millennium Management
New York
-$1M
3
BlackRock
BlackRock
New York
-$501K
4
Squarepoint
Squarepoint
New York
-$448K
5
Morgan Stanley
Morgan Stanley
New York
-$351K

KYNB Hedge Fund Activity: Q4 2023 in Review

100 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q4 2023, worth a combined $62.1M — up 5.4% from $59M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of KYNB and 12 opened new positions — a net loss of 10 holders — while 31 trimmed existing stakes and 33 added.

The largest buyer was Armistice Capital, adding an estimated $1.13M. The largest seller was Vanguard Group, cutting an estimated $1.22M.

  • 100 institutional investors held Kyntra Bio (KYNB) as of Q4 2023, down from 110 in Q3 2023.
  • Funds reported $62.1M of Kyntra Bio stock for Q4 2023, up 5.4% quarter-over-quarter.
  • 12 funds opened new Kyntra Bio positions in Q4 2023 and 22 closed out, a net change of -10 holders.
  • The largest Kyntra Bio buyer in Q4 2023 was Armistice Capital, an estimated $1.13M added.
  • The largest Kyntra Bio seller in Q4 2023 was Vanguard Group, an estimated $1.22M sold.

Based on aggregated 13F filings for Q4 2023.